A phase I/II study of Docetaxel (Taxotere, TM), Cisplatinum and Capecitabine (Xeloda, TM) (TCX) in patients with advanced oesophago-gastric cancer.

The phase I objective is to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of a chemotherapy regime called 'TCX' (Taxotere,TM, cisplatinum and Xeloda,TM) when it is given every 3 weeks in patients with advanced oesophagogastric cancer. The phase II objective is to determine the efficacy of the regime based on response rate using RECIST criteria and to confirm a recommended dose.